Regression of Peripheral Subclinical Enthesopathy in Therapy‐Naive Patients Treated With Ustekinumab for Moderate‐to‐Severe Chronic Plaque Psoriasis: A Fifty‐Two–Week, Prospective, Open‐Label Feasibility Study-Reference-Cited by-同舟云学术

Regression of Peripheral Subclinical Enthesopathy in Therapy‐Naive Patients Treated With Ustekinumab for Moderate‐to‐Severe Chronic Plaque Psoriasis: A Fifty‐Two–Week, Prospective, Open‐Label Feasibility Study

Published:2019-03-04 Issue:4 Volume:71 Page:626-631
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Savage Laura¹,Goodfield Mark²,Horton Laura¹,Watad Abdulla³,Hensor Elizabeth¹^ORCID,Emery Paul¹,Wakefield Richard¹,Wittmann Miriam⁴,McGonagle Dennis¹

Affiliation:

1. Leeds Institute of Rheumatic and Musculoskeletal MedicineUniversity of LeedsNIHR Leeds Biomedical Research CentreLeeds Teaching Hospitals NHS Trust Leeds UK

2. Leeds Teaching Hospitals NHS Trust Leeds UK

3. Leeds Institute of Rheumatic and Musculoskeletal MedicineUniversity of LeedsNIHR Leeds Biomedical Research CentreLeeds Teaching Hospitals NHS Trust, Leeds, UKSheba Medical CenterRamat‐Gan, Israel, and Tel‐Aviv University Tel‐Aviv Israel

4. Leeds Teaching Hospitals NHS TrustLeeds, UK, and University of Bradford Bradford UK

Funder

Janssen-Cilag Pharmaceuticals

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.40778

Reference18 articles.

1. The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study

2. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires